LAG3 and neoplasm: Since virus-associated type I IFN upregulates inhibitory receptors on CAR T cells (Fig. 4k, n) as well as PD-L1 and Galectin 9 on tumor cells (Supplementary Fig. 9B), we reevaluated the therapeutic potential of CAR T cells with VSVGFP in combination with a cocktail of anti-PD1, anti-TIM3, and anti-LAG3.